showed better response in 0.5mg/kg than PBO groups (OR=8.9, CI1. ps<0.05, respectively). Conclusion: the results did not find significant biomarkers to predict better respons to 0.5mg/kg ketamine but baseline high IL6 and low CRP level may possible do. Moderate reduction of TNF α level with 0.5mg/kg ketamine might be related to initial antiinflammtory effect.
Abstract
Objectives: Previous studies have reported associations between Temperament and Character Inventory (TCI) and the response to treatment in patients with major depressive disorder (MDD). We aimed to determine which TCI items could predict the response to treatment with paroxetine in patients with MDD and to provide cut-off values of the scores from these items. Methods: Seventy-three patients were enrolled in this study. Participants completed the TCI and were treated with paroxetine for six weeks. The Montgomery-Asberg Depression Rating Scale (MADRS) was used to evaluate depression. Participants were divided into responders and non-responders. We used a chi-squared test to identify the 10 items with the strongest association with treatment response from among all 240 items on the TCI. We rated the answers to each item associated with treatment response as a "1", and the answers associated with a non-response were rated as a "0". We calculated predictive scores using 10 models. Each model consisted of 1-10 scores of the best 1-10 items. We defined cut-off values for predicting treatment responses using a receiver operating characteristic (ROC) curve analysis. Results: Ranked by the strength of the association with treatment response, items 174, 137, 70, 237, 106, 191, 34, 232, 161 , and 215 significantly predicted treatment responses. All the models significantly predicted treatment response using a multiple logistic regression analysis. All predictive scores from models 1-10 significantly predicted treatment responses. The predictive score threshold of model 7 was 3/4 with an area under the curve of 0.825, and it showed the highest odds and likelihood ratios (19.3 and 8.86, respectively) . Conclusions: Some TCI items showed significant associations with the response to paroxetine treatment in the patients with MDD. We might predict the response using TCI predictive scoring, including items 174, 137, 70, 237, 106, 191 , and 34 and a cutoff value of 3/4.
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Effects of CYP2C19 genotype on steady-state plasma concentrations of escitalopram and desmetyl metabolite in Japanese depressed patients of S-enantiomer of citalopram were different between extensive metabolizers and poor metabolizers of CYP2C19 in healthy subjects and depressed patients. Thus, we studied the effects of polymorphisms of CYP2C19 gene on plasma drug concentrations in Japanese depressed patients. Methods: Subjects were 412 depressed patients receiving 5, 10, 15 and 20 mg once a day of escitalopram. The mean ± SD (range) of age and body weight were 43.1 ± 17.3 (19-80) years, and 60.3 ± 13.4 (34-91) kg, respectively. Sample collections were conducted 14-16 h after the bedtime dosing. Plasma concentrations of escitalopram and desmethylescitalopram were quantitated using HPLC. CYP2C19 genotypes were identified using PCR methods. The study was approved by the Ethics Committee of Hirosaki University Hospital, and written informed consent to participate in this study was obtained from the patients. Results: There was no difference in steady-state plasma concentrations of escitalopram in 5, 10, 15 or 20 mg of escitalopram. However, ANOVA showed a significant difference in dose-adjusted plasma concentration of escitalopram but not in dose adjusted plasma concentration of desmethylescitalopram. ANCOVA including age, sex and body weight showed significant differences in dose-adjusted plasma concentration of escitalopram and in ratio of desmethylescitalopram and escitalopram. Conclusion: These findings suggest that the CYP2C19 variants are associated with steady-state plasma concentration of escitalopram but not with desmethylescitalopram.
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Nicotinic acetylcholine receptor antagonists for treatment-resistant depression: A meta-analysis.
